Latest Content

Shifting to a higher and less frequent dose of axalitamab was tolerable and feasible in patients with chronic GVHD.

KRd demonstrated higher PFS, deeper response, and greater MRD negativity compared with VRd in newly diagnosed multiple myeloma.

The combination of odronextamab with CHOP chemotherapy showed early efficacy in patients with untreated diffuse large B-cell lymphoma.

Nearly one-third of families of children with acute lymphoblastic leukemia developed “catastrophic” financial toxicity during the patient’s treatment.

Higher LDH levels were linked with poorer survival outcomes in patients with relapsed and refractory multiple myeloma who received elranatamab.

The primary end point of EFS was met in patients given conditioning without TBI, along with allogeneic HCT in a subset of patients with B-ALL.

Fixed-duration venetoclax combined obinutuzumab or ibrutinib produced noninferior PFS compared with continuous ibrutinib monotherapy.

Race was identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.

Danielle Blair, RN, BSN, OCN, CCRP, explains what her role as an adolescent and young adult nurse navigator in oncology entails.

Nurses play a key role in helping patients with cervical cancer weigh the risks and benefits of radiation and concurrent chemotherapy.

The FDA has approved pirtobrutinib treatment for adults with relapsed/refractory CLL/SLL who have received prior treatment with a covalent BTK inhibitor.

What should nurses know about treating patients with KRAS G12C-mutated metastatic colorectal cancer using adagrasib and cetuximab?

A patient acuity model drove efficient and safe staffing through data from a natural language processing model informed by oncology nurse insights.